Spinal muscarinic cholinergic and nitric oxide systems in cardiovascular regulation

David S. Feldman, Alvin V Terry, Jerry J. Buccafusco

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Pharmacological activation of muscarinic receptors located in the thoracic spinal cord evokes a marked increase in blood pressure and heart rate. We have previously demonstrated that the cardiovascular response to stimulation of spinal cord muscarinic cholinergic receptors is dependent upon a pharmacologically described ascending spine-bulbar pathway. The purpose of the study was to determine whether the blood pressure and heart rate responses to intrathecaI (i.t.) injection of the muscarinic cholinergic receptor agonist carbachol are mediated by a local nitric oxide (NO)-generating system. Freely moving rats were previously prepared with chronic indwelling i.t. and intra-arterial catheters. Both the presser and tachycardia responses produced by i.t. injection of carbachol were inhibited in a dose-dependent manner by i.t. pre-treatment with the NO synthase inhibitor N-ω-Nitro-L-arginine methylester (L-NAME). To confirm the site of action of the drugs employed in conscious rats, a separate group of rats was anesthetized, and using surgical procedures previously developed in this laboratory, drug distribution was limited specifically to the lower thoracic spinal cord. When carbachol was administered by i.t. injection and localized to the lower thoracic area, muscarinic cholinergic receptor stimulation again produced a marked presser response, but without the accompanying tachycardia. The ability of N-ω-Nitro-L-arginine methylester (L-NAME) to inhibit the presser response to carbachol in conscious rats was confirmed in anesthetized rats, although higher doses of L-NAME than those employed in conscious rats were required. L-NAME-induced inhibition of the carbachol-evoked presser response was reversed by the L-, but not the D-isomer, of arginine. Moreover, i.t. pre-treatment with Methylene blue, that interferes with NO production and function, effectively inhibited the expression of the presser response to i.t. injection of carbachol. The 'anti-muscarinic' action of L-NAME was not due to a direct interaction with spinal muscarinic receptors, as L-NAME did not significantly displace [3Hlmethylscopolamine from spinal cord membranes in vitro. The results of this study support the hypothesis that spinal muscarinic cholinergic receptors participate in a sympathoexcitatory pathway that interacts either directly or indirectly with a local NO-generating system involved in the regulation of blood pressure.

Original languageEnglish (US)
Pages (from-to)211-220
Number of pages10
JournalEuropean Journal of Pharmacology
Volume313
Issue number3
DOIs
StatePublished - Oct 17 1996

Fingerprint

NG-Nitroarginine Methyl Ester
Carbachol
Muscarinic Receptors
Cardiovascular System
Cholinergic Agents
Nitric Oxide
Cholinergic Receptors
Arginine
Spinal Cord
Injections
Thorax
Blood Pressure
Tachycardia
Heart Rate
Spinal Cord Stimulation
Muscarinic Agonists
Methylene Blue
Nitric Oxide Synthase
Pharmaceutical Preparations
Spine

Keywords

  • Blood pressure
  • Hypertension
  • Muscarinic receptor
  • N(ω)-Nitro-L-arginine methyl ester (L-NAME)
  • Nitric oxide (NO)
  • Spinal cord

ASJC Scopus subject areas

  • Pharmacology

Cite this

Spinal muscarinic cholinergic and nitric oxide systems in cardiovascular regulation. / Feldman, David S.; Terry, Alvin V; Buccafusco, Jerry J.

In: European Journal of Pharmacology, Vol. 313, No. 3, 17.10.1996, p. 211-220.

Research output: Contribution to journalArticle

@article{23a1a7514017417591a7fa6cbd393f0a,
title = "Spinal muscarinic cholinergic and nitric oxide systems in cardiovascular regulation",
abstract = "Pharmacological activation of muscarinic receptors located in the thoracic spinal cord evokes a marked increase in blood pressure and heart rate. We have previously demonstrated that the cardiovascular response to stimulation of spinal cord muscarinic cholinergic receptors is dependent upon a pharmacologically described ascending spine-bulbar pathway. The purpose of the study was to determine whether the blood pressure and heart rate responses to intrathecaI (i.t.) injection of the muscarinic cholinergic receptor agonist carbachol are mediated by a local nitric oxide (NO)-generating system. Freely moving rats were previously prepared with chronic indwelling i.t. and intra-arterial catheters. Both the presser and tachycardia responses produced by i.t. injection of carbachol were inhibited in a dose-dependent manner by i.t. pre-treatment with the NO synthase inhibitor N-ω-Nitro-L-arginine methylester (L-NAME). To confirm the site of action of the drugs employed in conscious rats, a separate group of rats was anesthetized, and using surgical procedures previously developed in this laboratory, drug distribution was limited specifically to the lower thoracic spinal cord. When carbachol was administered by i.t. injection and localized to the lower thoracic area, muscarinic cholinergic receptor stimulation again produced a marked presser response, but without the accompanying tachycardia. The ability of N-ω-Nitro-L-arginine methylester (L-NAME) to inhibit the presser response to carbachol in conscious rats was confirmed in anesthetized rats, although higher doses of L-NAME than those employed in conscious rats were required. L-NAME-induced inhibition of the carbachol-evoked presser response was reversed by the L-, but not the D-isomer, of arginine. Moreover, i.t. pre-treatment with Methylene blue, that interferes with NO production and function, effectively inhibited the expression of the presser response to i.t. injection of carbachol. The 'anti-muscarinic' action of L-NAME was not due to a direct interaction with spinal muscarinic receptors, as L-NAME did not significantly displace [3Hlmethylscopolamine from spinal cord membranes in vitro. The results of this study support the hypothesis that spinal muscarinic cholinergic receptors participate in a sympathoexcitatory pathway that interacts either directly or indirectly with a local NO-generating system involved in the regulation of blood pressure.",
keywords = "Blood pressure, Hypertension, Muscarinic receptor, N(ω)-Nitro-L-arginine methyl ester (L-NAME), Nitric oxide (NO), Spinal cord",
author = "Feldman, {David S.} and Terry, {Alvin V} and Buccafusco, {Jerry J.}",
year = "1996",
month = "10",
day = "17",
doi = "10.1016/0014-2999(96)00513-4",
language = "English (US)",
volume = "313",
pages = "211--220",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Spinal muscarinic cholinergic and nitric oxide systems in cardiovascular regulation

AU - Feldman, David S.

AU - Terry, Alvin V

AU - Buccafusco, Jerry J.

PY - 1996/10/17

Y1 - 1996/10/17

N2 - Pharmacological activation of muscarinic receptors located in the thoracic spinal cord evokes a marked increase in blood pressure and heart rate. We have previously demonstrated that the cardiovascular response to stimulation of spinal cord muscarinic cholinergic receptors is dependent upon a pharmacologically described ascending spine-bulbar pathway. The purpose of the study was to determine whether the blood pressure and heart rate responses to intrathecaI (i.t.) injection of the muscarinic cholinergic receptor agonist carbachol are mediated by a local nitric oxide (NO)-generating system. Freely moving rats were previously prepared with chronic indwelling i.t. and intra-arterial catheters. Both the presser and tachycardia responses produced by i.t. injection of carbachol were inhibited in a dose-dependent manner by i.t. pre-treatment with the NO synthase inhibitor N-ω-Nitro-L-arginine methylester (L-NAME). To confirm the site of action of the drugs employed in conscious rats, a separate group of rats was anesthetized, and using surgical procedures previously developed in this laboratory, drug distribution was limited specifically to the lower thoracic spinal cord. When carbachol was administered by i.t. injection and localized to the lower thoracic area, muscarinic cholinergic receptor stimulation again produced a marked presser response, but without the accompanying tachycardia. The ability of N-ω-Nitro-L-arginine methylester (L-NAME) to inhibit the presser response to carbachol in conscious rats was confirmed in anesthetized rats, although higher doses of L-NAME than those employed in conscious rats were required. L-NAME-induced inhibition of the carbachol-evoked presser response was reversed by the L-, but not the D-isomer, of arginine. Moreover, i.t. pre-treatment with Methylene blue, that interferes with NO production and function, effectively inhibited the expression of the presser response to i.t. injection of carbachol. The 'anti-muscarinic' action of L-NAME was not due to a direct interaction with spinal muscarinic receptors, as L-NAME did not significantly displace [3Hlmethylscopolamine from spinal cord membranes in vitro. The results of this study support the hypothesis that spinal muscarinic cholinergic receptors participate in a sympathoexcitatory pathway that interacts either directly or indirectly with a local NO-generating system involved in the regulation of blood pressure.

AB - Pharmacological activation of muscarinic receptors located in the thoracic spinal cord evokes a marked increase in blood pressure and heart rate. We have previously demonstrated that the cardiovascular response to stimulation of spinal cord muscarinic cholinergic receptors is dependent upon a pharmacologically described ascending spine-bulbar pathway. The purpose of the study was to determine whether the blood pressure and heart rate responses to intrathecaI (i.t.) injection of the muscarinic cholinergic receptor agonist carbachol are mediated by a local nitric oxide (NO)-generating system. Freely moving rats were previously prepared with chronic indwelling i.t. and intra-arterial catheters. Both the presser and tachycardia responses produced by i.t. injection of carbachol were inhibited in a dose-dependent manner by i.t. pre-treatment with the NO synthase inhibitor N-ω-Nitro-L-arginine methylester (L-NAME). To confirm the site of action of the drugs employed in conscious rats, a separate group of rats was anesthetized, and using surgical procedures previously developed in this laboratory, drug distribution was limited specifically to the lower thoracic spinal cord. When carbachol was administered by i.t. injection and localized to the lower thoracic area, muscarinic cholinergic receptor stimulation again produced a marked presser response, but without the accompanying tachycardia. The ability of N-ω-Nitro-L-arginine methylester (L-NAME) to inhibit the presser response to carbachol in conscious rats was confirmed in anesthetized rats, although higher doses of L-NAME than those employed in conscious rats were required. L-NAME-induced inhibition of the carbachol-evoked presser response was reversed by the L-, but not the D-isomer, of arginine. Moreover, i.t. pre-treatment with Methylene blue, that interferes with NO production and function, effectively inhibited the expression of the presser response to i.t. injection of carbachol. The 'anti-muscarinic' action of L-NAME was not due to a direct interaction with spinal muscarinic receptors, as L-NAME did not significantly displace [3Hlmethylscopolamine from spinal cord membranes in vitro. The results of this study support the hypothesis that spinal muscarinic cholinergic receptors participate in a sympathoexcitatory pathway that interacts either directly or indirectly with a local NO-generating system involved in the regulation of blood pressure.

KW - Blood pressure

KW - Hypertension

KW - Muscarinic receptor

KW - N(ω)-Nitro-L-arginine methyl ester (L-NAME)

KW - Nitric oxide (NO)

KW - Spinal cord

UR - http://www.scopus.com/inward/record.url?scp=0030591765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030591765&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(96)00513-4

DO - 10.1016/0014-2999(96)00513-4

M3 - Article

VL - 313

SP - 211

EP - 220

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -